EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

August 31, 2011

Study Completion Date

May 31, 2012

Conditions

Lymphoma, Small LymphocyticLeukemia, Lymphocytic, Chronic

Interventions

DRUG

cenersen sodium

2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4

DRUG

Rituximab

375 mg/m2 on day 2

DRUG

Cyclophosphamide

250 mg/m2 on days 2, 3, and 4

DRUG

Fludarabine

25 mg/m2 on days 2, 3, and 4

Trial Locations (1)

Duke University Medical Center, Durham